APLLTD logo

Alembic Pharmaceuticals Limited Stock Price

NSEI:APLLTD Community·₹179.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 5 Fair Values set on narratives written by author

APLLTD Share Price Performance

₹910.40
-307.55 (-25.25%)
28.6% undervalued intrinsic discount
₹1,275.00
Fair Value
₹910.40
-307.55 (-25.25%)
28.6% undervalued intrinsic discount
₹1,275.00
Fair Value
Price ₹910.40
AnalystHighTarget ₹1,275.00
AnalystConsensusTarget ₹1,056.64
AnalystLowTarget ₹900.00

APLLTD Community Narratives

AnalystHighTarget·Updated
Fair Value ₹1.28k 28.6% undervalued intrinsic discount

Aging Populations And Emerging Markets Will Transform Pharmaceutical Opportunities

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value ₹1.06k 13.8% undervalued intrinsic discount

US Product Launches And India Execution Will Expand Reach

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystLowTarget·Updated
Fair Value ₹900 1.2% overvalued intrinsic discount

Regulatory Scrutiny And Supply Issues Will Squeeze Pharma Prospects

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

APLLTD Community Fair Values

Recent APLLTD News & Updates

Analysts Are Updating Their Alembic Pharmaceuticals Limited (NSE:APLLTD) Estimates After Its First-Quarter Results

Aug 08
Analysts Are Updating Their Alembic Pharmaceuticals Limited (NSE:APLLTD) Estimates After Its First-Quarter Results

Alembic Pharmaceuticals Limited's (NSE:APLLTD) P/E Still Appears To Be Reasonable

Jul 11
Alembic Pharmaceuticals Limited's (NSE:APLLTD) P/E Still Appears To Be Reasonable

Here's What Analysts Are Forecasting For Alembic Pharmaceuticals Limited (NSE:APLLTD) After Its Annual Results

May 11
Here's What Analysts Are Forecasting For Alembic Pharmaceuticals Limited (NSE:APLLTD) After Its Annual Results

Alembic Pharmaceuticals Limited Key Details

₹68.2b

Revenue

₹18.9b

Cost of Revenue

₹49.3b

Gross Profit

₹43.2b

Other Expenses

₹6.0b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
30.68
Gross Margin
72.23%
Net Profit Margin
8.84%
Debt/Equity Ratio
24.2%

Alembic Pharmaceuticals Limited Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and fair value.

1 Risk
3 Rewards

About APLLTD

Founded
1907
Employees
16571
CEO
Chirayu Amin
WebsiteView website
alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

Indian Market Performance

  • 7 Days: 1.5%
  • 3 Months: -1.7%
  • 1 Year: -4.7%
  • Year to Date: 0.7%
Over the last 7 days, the market has risen 1.5%, driven by gains of 2.3% in the Financials sector. In contrast, the market has seen a decline of 4.7% over the last 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›